Monica Lövestam-Adrian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3943587/publications.pdf

Version: 2024-02-01

		1163117	888059	
17	340	8	17	
papers	citations	h-index	g-index	
17	17	17	530	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	Citations
1	What about the fellow eye in treatment of neovascular ageâ€related macular degeneration? Analysis of data from the Swedish macula register. Acta Ophthalmologica, 2022, , .	1.1	4
2	Electrophysiological evaluation and 18 -month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration. Documenta Ophthalmologica, 2022, , 1 .	2.2	1
3	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 567-574.	1.9	14
4	Exploration of realâ€world outcomes and treatment patterns in patients treated with antiâ€vascular endothelial growth factors for neovascular ageâ€related macular degeneration in Sweden. Acta Ophthalmologica, 2021, , .	1.1	1
5	A novel tool to assess the quality of RWE to guide the management of retinal disease. Acta Ophthalmologica, 2021, 99, 604-610.	1.1	3
6	Twelve per cent of 6142 eyes treated for neovascular ageâ€related macular degeneration (nAMD) presented with low visual outcome within 2Âyears. Analysis from the Swedish Macula Registry (SMR). Acta Ophthalmologica, 2020, 98, 274-278.	1.1	5
7	Treatment algorithm with dexamethasone intravitreal implant in patients with diabetic macular edema. Acta Ophthalmologica, 2020, 98, e528-e529.	1.1	2
8	CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 599-611.	1.7	18
9	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1149-1156.	1.9	97
10	Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet ageâ€related macular degeneration: data from the ⟨scp⟩INSIGHT⟨/scp⟩ study using the Swedish Macula Register. Acta Ophthalmologica, 2019, 97, 91-98.	1.1	16
11	Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. Diabetes, Obesity and Metabolism, 2019, 21, 467-478.	4.4	110
12	Treatment for neovascular ageâ€related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. Acta Ophthalmologica, 2017, 95, 787-795.	1.1	29
13	No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration. Clinical Ophthalmology, 2017, Volume 11, 1105-1111.	1.8	3
14	Multifocal Visual Evoked Potentials (mfVEP) in Diabetic Patients with and without Polyneuropathy. Open Ophthalmology Journal, 2012, 6, 98-103.	0.2	4
15	Multifocal electroretinography amplitudes increase after photocoagulation in areas with increased retinal thickness and hard exudates. Acta Ophthalmologica, 2010, 88, 188-192.	1.1	10
16	Vitrectomy Seems to be Beneficial for Advanced Diffuse Diabetic Macular Oedema not Responding to Laser Treatment. International Ophthalmology, 2006, 26, 21-26.	1.4	4
17	Macular function assessed with mfERG before and after panretinal photocoagulation in patients with proliferative diabetic retinopathy. Documenta Ophthalmologica, 2004, 109, 115-121.	2.2	19